Financial Highlights & Revenue Break Up
40,000
35,000
30,000
25,000
20,000
10,000
0

25,986
FY 20
32,375
FY 21
37,649
FY 22
Revenue
35,000
30,000
25,000
20,000
10,000
5,000
0

16,918
FY 18
22,792
FY 19
25,986
FY 20
32,375
FY 21
37,649
FY 22
Revenue
35%
30%
25%
15%
10%
5%
0%

20.2%
FY 20
26.4%
FY 21
19.2%
FY 22
EBITDA %
35%
30%
25%
15%
10%
5%
0%

16.8%
FY 19
20.2%
FY 20
26.4%
FY 21
EBITDA %
9,000
7,500
6,000
4,500
3,000
1,500
0

5,253
FY 20
8,552
FY 21
7,222
FY 22
EBITDA
9,000
7,500
6,000
4,500
3,000
1,500
0

3,840
FY 19
5,253
FY 20
8,552
FY 21
EBITDA
7,000
6,000
5,000
3,000
2,500
2,000
0

3,355
FY 20
5,495
FY 21
4,128
FY 22
PAT
7,000
6,000
5,000
3,000
2,500
2,000
0

2,364
FY 19
3,355
FY 20
5,495
FY 21
PAT
23%
19%
14%
9%
6%
3%
0%

12.9%
FY 20
17.0%
FY 21
11.0%
FY 22
PAT%
23%
19%
14%
9%
6%
3%
0%

10.4%
FY 19
12.9%
FY 20
17.0%
FY 21
PAT%
26,000
22,000
18,000
15,000
10,000
5,000
0

18,437
FY 20
21,733
FY 21
25,871
FY 22
Networth
26,000
22,000
18,000
15,000
10,000
5,000
0

15,295
FY 19
18,437
FY 20
21,732.74
FY 21
Networth
30,000
25,000
20,000
15,000
10,000
5,000
0

18,752
FY 20
21,302
FY 21
24,395
FY 22
Gross Block
30,000
25,000
20,000
15,000
10,000
5,000
0

14,729
FY 19
18,752
FY 20
21451.49
FY 21
Gross Block
Break-up of Consolidated Revenue as per Geography
FY'22 (Rs. in Mn)19,542
52%
7,902
21%
3,811
10%
4,415
12%
1,979
5%

North America
Europe
Row
Latin America
India
Break-up of Consolidated Revenue as per Business Segment
FY'22 (Rs. in Mn)19,442
52%
9,751
26%
8,456
22%

PFI
API
FD
Break-up of Consolidated Revenue as per Molecule
FY'22 (Rs. in Mn)14,282
38%
9,410
25%
4,768
13%
1,100
3%
1,114
3%
6,974
19%

Paracetamol
Metformin
Guaifenesin
Ibuprofen
Methocarbamol
Others
Break-up of Consolidated Revenue as per Geography
FY'21 (Rs. in Mn)17,451
54%
5,674
18%
2,925
9%
4,525
14%
1,800
6%

North America
Europe
Row
Latin America
India
Break-up of Consolidated Revenue as per Business Segment
FY'21 (Rs. in Mn)16,989
53%
9,124
28%
6,262
19%

PFI
API
FD
Break-up of Consolidated Revenue as per Molecule
FY'21 (Rs. in Mn)10,939
34%
8,498
26%
5,808.2
18%
1,051.7
3%
928.6
3%
5,150
16%

Paracetamol
Metformin
Guaifenesin
Ibuprofen
Methocarbamol
Others
Break-up of Consolidated Revenue as per Business Segment
FY'20 (Rs. in Mn)13,602
52%
8,170
31%
4,214
16%

API
PFI
FD